Youth Cannabis Use and Disorder: Surveys, Diagnosis, Risks, and Policy
This hub covers adolescent cannabis use and cannabis use disorder (CUD): how it is measured, how it is diagnosed, and what is known about risk. It explains the difference between self-reported survey data, such as Monitoring the Future and the CDC's Youth Risk Behavior Survey, and clinically diagnosed disorder recorded in health-system data. It also covers DSM-5 criteria, brain development concerns, high-potency products, legalization and age-restriction policy, screening tools, and treatment options for teens. A recent large study of roughly 637,000 adolescents suggests that surveys may miss a rise in diagnosed disorder, and this page places that finding in context.

Executive Summary
Youth cannabis use is a measurement problem as much as a policy problem: self-reported teen use surveys have shown flat or falling rates while clinical diagnoses of cannabis use disorder may be moving on a different track. A study of roughly 637,000 adolescents, reported September 23, 2026 by Lassen County News, suggests that school-based surveys may be missing a rise in diagnosed disorder. This hub explains why that gap can exist, what the evidence says, and what operators, regulators and clinicians should do about it.
The core facts are well established. Cannabis use disorder (CUD) is a formal diagnosis in the DSM-5, which in 2013 merged the older "abuse" and "dependence" categories into one condition graded mild, moderate or severe by the number of criteria met (2-3, 4-5, or 6 or more of 11). The National Institute on Drug Abuse (NIDA) has said that people who start using in adolescence face a higher risk of developing the disorder than those who start as adults. NIDA's figure is about 1 in 6 for adolescent starters, versus about 1 in 10 for users overall.
The data sources answer different questions. Monitoring the Future (MTF), the CDC's Youth Risk Behavior Survey (YRBS) and SAMHSA's National Survey on Drug Use and Health (NSDUH) ask teens what they did. Clinical and claims datasets record what clinicians diagnosed and billed. Those can diverge for reasons that have nothing to do with fraud: better screening, changed coding, more treatment-seeking, higher-potency products, and the students surveys never reach.
For the industry, the stakes are concrete. Every California, Colorado or New York license depends on a social license built partly on the promise that legal markets keep cannabis from minors. A credible signal of rising adolescent disorder invites potency caps, packaging mandates, advertising limits and tighter enforcement.
Why This Matters
Adolescent cannabis disorder sits at the intersection of public health, a multibillion-dollar legal industry, and an unresolved federal scheduling fight. Each group has a different stake in how it is measured.
Patients and families
Adolescence is a period of active brain development. NIDA's Nora Volkow has repeatedly summarized research linking heavy adolescent use to impaired learning, attention and memory, and to higher rates of co-occurring anxiety, depression and other substance use. Causation is contested, and many of those who use heavily also have other risk factors. But clinicians treating teens with CUD report that it rarely occurs alone, which complicates both diagnosis and treatment.
No medication is FDA-approved for CUD. Treatment relies on behavioral approaches: motivational enhancement therapy, cognitive behavioral therapy, contingency management and family-based therapy such as multidimensional family therapy. Access to adolescent-specific programs is uneven, especially outside metropolitan areas such as those in rural northern California, where the Lassen County News report originated.
Regulators and legislators
Legislators in every adult-use state have had to defend the age-21 rule and licensed-retail model against evidence of youth harm. A new signal showing diagnoses rising while surveys read flat gives opponents of legalization a fresh argument. It gives reform advocates a reason to push for better measurement rather than abandoning the model.
Operators and investors
For a multistate operator (MSO), youth-related regulation shows up as concrete costs: opaque child-resistant packaging, restrictions on cartoon-like branding, mandatory THC labeling, potency limits and ID-verification rules. Because 280E already strips most deductions from plant-touching businesses, added compliance expense falls on thin after-tax margins. Capital markets price in regulatory risk, and youth-harm headlines are a recurring source of it.
Scale of the question
A 637,000-adolescent sample is large by the standards of this field. MTF surveys tens of thousands of students in grades 8, 10 and 12 each year. A dataset many times that size, drawn from clinical or administrative records, can detect small shifts that a survey cannot. It also measures a different thing, which is why the two should be read together and not played against each other.
Background and History
The modern debate over teen cannabis disorder runs from the 1970s survey era through the 2012 legalization votes to today's high-potency, multi-product market.
1970s-1990s: Surveys begin, use peaks and falls
The Monitoring the Future study, based at the University of Michigan and funded by NIDA, began surveying high school seniors in 1975. Its early data showed a sharp peak in adolescent cannabis use in the late 1970s, a decline through the 1980s, and a rebound in the 1990s. That pattern, driven partly by shifting perceptions of risk, became a core finding: when teens believe cannabis is dangerous, use falls, and when that belief erodes, use rises.
1996: Medical cannabis begins
California's Proposition 215 in 1996 created the first modern state medical cannabis program. Researchers and prevention groups began asking whether the spread of medical programs would soften adolescent attitudes. Studies of that question produced mixed results, a pattern that has persisted in every subsequent policy wave.
2013: DSM-5 redefines the disorder
The American Psychiatric Association's DSM-5 replaced separate abuse and dependence diagnoses with a single cannabis use disorder on a severity spectrum. The change affected how prevalence is counted. Earlier diagnoses and later ones are not perfectly comparable, a caveat for any long-run trend analysis, including those that rely on ICD-10 "F12" billing codes.
2012-2014: Colorado and Washington open the legal era
Voters in Colorado (Amendment 64) and Washington (Initiative 502) approved adult-use legalization in November 2012. Licensed retail sales began in Colorado in January 2014 and in Washington in July 2014. Alaska, Oregon and the District of Columbia followed. Every one of these laws set the purchase age at 21, mirroring alcohol.
2015-2019: Studies disagree on legalization's effect
Researchers divided. A 2017 JAMA Pediatrics analysis by Magdalena Cerdá and colleagues found increases in adolescent use in Washington following legalization, alongside declining perceived harm. Analyses by economist D. Mark Anderson and co-authors, published in 2019, found no increase in teen use, and in some specifications a decline, following legalization across several states. The disagreement stems largely from differences in methods, comparison states and survey years, and it has not been fully resolved.
2018: Canada legalizes nationally
Canada's Cannabis Act took effect in October 2018, creating the first national legal market in a G7 country. Health Canada has since funded surveys of youth use, giving researchers a second legal jurisdiction in which to test whether survey and clinical measures agree.
2018-2022: Potency and product shifts
The University of Mississippi's Potency Monitoring Project documented average THC content in seized flower rising from roughly 4% in the mid-1990s to above 15% by the late 2010s. Concentrates, vaporizers and edibles added products with much higher or less predictable doses. The 2018 Farm Bill's hemp provisions also opened a market in intoxicating hemp-derived products such as delta-8 THC, often sold outside age-verified dispensaries.
2020-2021: Pandemic disruption
The COVID-19 pandemic disrupted school-based surveys. Fieldwork was interrupted, remote schooling changed who could be sampled, and mental-health strain among adolescents rose. Trend lines that cross 2020 carry methodological asterisks, which remains relevant to comparing survey and clinical series.
2022-2024: Survey lows and federal movement
MTF and other surveys reported adolescent use below pre-pandemic levels in several measures, a finding public health officials welcomed. In May 2024, the DEA and Department of Justice published a proposed rule (NPRM) to move cannabis from Schedule I to Schedule III of the Controlled Substances Act, 21 U.S.C. § 812.
2025-2026: Hemp restrictions, rescheduling push and the new study
Congress passed an appropriations measure in November 2025 that redefined hemp to sharply limit intoxicating products, with a delayed effective date roughly a year later. A December 2025 executive order from the White House directed expedited rescheduling work. Verify current status with the DEA and the Federal Register before relying on any date here. On September 23, 2026, Lassen County News reported the 637,000-adolescent study suggesting that teen surveys may be missing a rise in diagnosed disorder.
Key Players
A small set of federal agencies, academic survey teams, clinical bodies and advocacy groups shapes both the data and the policy response.
NIDA and the National Institutes of Health
NIDA, led by director Nora Volkow, funds MTF and the Adolescent Brain Cognitive Development (ABCD) Study, which follows roughly 11,800 children. It is the main federal source for the proposition that adolescent-onset use carries elevated disorder risk.
SAMHSA
The Substance Abuse and Mental Health Services Administration runs NSDUH, a household survey estimating past-year CUD among those aged 12-17. Because NSDUH is household-based, it reaches some adolescents that school surveys miss, but it still relies on self-report and parental proximity.
CDC
The Centers for Disease Control and Prevention administers the biennial Youth Risk Behavior Survey among high school students. Like MTF, it samples students in school.
University of Michigan Monitoring the Future team
Led in recent years by Richard Miech, the MTF team publishes annual findings on use, perceived risk and availability. Its analyses are the benchmark against which any claim of a survey blind spot is measured.
FDA and DEA
The FDA regulates marketing claims and has issued warning letters over edible products that mimic popular snack brands, a youth-appeal concern. The DEA controls scheduling. A move to Schedule III would not by itself legalize adult-use sales or change age rules, but it would alter research access and the federal tax posture of operators.
American Academy of Pediatrics
Frequently asked questions
What is cannabis use disorder in teens?
Cannabis use disorder (CUD) is a diagnosis in the DSM-5 describing problematic, impairing cannabis use. Clinicians look at 11 criteria, including using more than intended, failed attempts to cut back, cravings, tolerance, withdrawal, and giving up activities. Two to three criteria indicate mild CUD, four to five moderate, and six or more severe. The same criteria apply to adolescents and adults.
Why might teen surveys miss a rise in diagnosed cannabis disorder?
Surveys such as Monitoring the Future and the Youth Risk Behavior Survey ask students whether they used cannabis, typically in the past 30 days or year. Diagnosis data from health systems capture clinical problems, including heavier or higher-potency use, screening changes, and greater clinician detection. Surveys can also miss dropouts, absent students, and underreporting. Use rates can stay flat while diagnosed disorder rises.
What did the study of 637,000 adolescents find?
A study reported by Lassen County News in September 2026 analyzed about 637,000 adolescents and found that surveys may be missing a rise in diagnosed cannabis use disorder. The reporting suggests self-reported use and clinical diagnoses can tell different stories. Readers should consult the original peer-reviewed paper for methods, time frame, and exact figures.
How common is cannabis use among U.S. teens?
Federal surveys track this each year. Monitoring the Future, funded by the National Institute on Drug Abuse (NIDA) and run by the University of Michigan, surveys 8th, 10th, and 12th graders. Cannabis is the most commonly used illicit drug among U.S. teens, and use rises with grade level. The CDC's Youth Risk Behavior Survey provides a separate estimate for high schoolers.
Does legalization increase teen cannabis use?
The evidence is mixed. Many analyses of state adult-use legalization, including those drawing on national surveys, have found little or no clear increase in self-reported teen use overall. Researchers continue to study subtler outcomes, such as product type, potency, access, emergency visits, and diagnosed disorder. Results vary by state, study design, and time period.
What are the health risks of cannabis use during adolescence?
Adolescent brains continue developing into the mid-20s. Research links early, frequent use to higher risk of dependence, impaired attention and memory, and academic problems. Associations with anxiety, depression, and psychosis, especially with high-potency THC, have also been reported. Causation is hard to prove because other factors, such as family history and other substance use, also play a role.
What are signs a teen may have a cannabis use problem?
Warning signs include declining grades, loss of interest in activities, changes in friend groups, irritability, sleep or appetite changes, and secretive behavior. Specific CUD signs include failed attempts to stop, strong cravings, and withdrawal symptoms such as restlessness or insomnia. None is definitive alone. A clinician or pediatrician can screen with validated tools like the CRAFFT.
How is adolescent cannabis use disorder treated?
Behavioral therapies are the main treatment. They include cognitive behavioral therapy, motivational enhancement therapy, contingency management, and family-based approaches such as multidimensional family therapy. No FDA-approved medication exists for cannabis use disorder in any age group. Co-occurring conditions such as anxiety, depression, or ADHD are often treated at the same time.
Is today's cannabis more dangerous for teens than in the past?
THC concentrations in flower, vapes, dabs, and edibles are generally higher than in decades past, according to NIDA and the University of Mississippi's potency monitoring project. Higher potency is associated with greater risk of dependence and acute adverse effects. Researchers are still working out how product type affects adolescent outcomes.
What is the legal age for cannabis in states with legal markets?
Every state with an adult-use market sets the minimum purchase age at 21. Medical programs may allow minors with a caregiver's consent and physician recommendation in some states. Federal law still classifies cannabis as a controlled substance. Underage possession penalties vary by state, with many using civil fines or diversion programs.
Where can parents and teens find help?
The SAMHSA National Helpline (1-800-662-HELP) is free, confidential, and open 24/7. SAMHSA's FindTreatment.gov lists treatment providers. Pediatricians can also screen and refer. The American Academy of Pediatrics recommends routine substance use screening during adolescent visits. In an emergency, call 911 or 988 for crisis support.
The cannabis newsletter you forward to your team.
Federal policy, market data, grower alerts, and the one story that matters today. Sent every weekday at 7am. Free.
No spam. Unsubscribe with one click. 21+ only.